IL15 and neuroblastoma: The combination of dinutuximab, N-803 (IL-15 superagonist), and adoptive NK cell transfer increased NK cell-mediated cytotoxicity in vitro by stimulating the antibody-dependent cellular cytotoxicity of NK cells, and increased the survival of NB xenograft models [212].